EPHX2 and diffuse large B-cell lymphoma: For DFS, EPHX2 was more likely to be a favorable factor in KIRC, PAAD, PRAD, and UVM, but deleterious in lymphoid neoplasm diffuse large B‐cell lymphoma (DLBC) and LGG (Figure 4C).